DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,401 filers reported holding DANAHER CORPORATION in Q2 2019. The put-call ratio across all filers is 0.58 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $14,106,282 | +0.8% | 56,459 | +0.8% | 2.76% | +1.0% |
Q1 2024 | $13,989,814 | +8.6% | 56,022 | +0.6% | 2.74% | -3.8% |
Q4 2023 | $12,881,706 | -0.9% | 55,683 | +6.3% | 2.85% | -6.7% |
Q3 2023 | $12,998,952 | +3.7% | 52,394 | +0.3% | 3.05% | +4.3% |
Q2 2023 | $12,536,880 | -0.2% | 52,237 | +4.8% | 2.92% | -2.2% |
Q1 2023 | $12,560,666 | -4.8% | 49,836 | +0.3% | 2.99% | -7.6% |
Q4 2022 | $13,194,294 | +4.3% | 49,711 | +1.5% | 3.24% | -7.0% |
Q3 2022 | $12,656,000 | +2.7% | 48,998 | +0.8% | 3.48% | +6.9% |
Q2 2022 | $12,318,000 | -12.9% | 48,587 | +0.8% | 3.26% | +1.9% |
Q1 2022 | $14,136,000 | -6.0% | 48,193 | +5.4% | 3.20% | +3.2% |
Q4 2021 | $15,042,000 | +7.8% | 45,718 | -0.3% | 3.10% | +3.9% |
Q3 2021 | $13,955,000 | -1.2% | 45,839 | -12.9% | 2.98% | -1.8% |
Q2 2021 | $14,120,000 | +19.9% | 52,617 | +0.6% | 3.04% | +16.3% |
Q1 2021 | $11,776,000 | +0.3% | 52,317 | -1.0% | 2.61% | -9.9% |
Q4 2020 | $11,739,000 | +2.2% | 52,847 | -0.9% | 2.90% | -16.7% |
Q3 2020 | $11,487,000 | +21.8% | 53,347 | +0.0% | 3.48% | +3.8% |
Q2 2020 | $9,432,000 | +18.0% | 53,342 | -7.6% | 3.35% | -19.0% |
Q1 2020 | $7,993,000 | -4.5% | 57,752 | +5.9% | 4.14% | +4.7% |
Q4 2019 | $8,370,000 | +4.1% | 54,534 | -2.1% | 3.95% | -9.3% |
Q3 2019 | $8,042,000 | +1.5% | 55,684 | +0.4% | 4.36% | -5.2% |
Q2 2019 | $7,925,000 | +7.4% | 55,454 | -0.8% | 4.60% | +6.3% |
Q1 2019 | $7,377,000 | +13.0% | 55,879 | -11.7% | 4.33% | +1.3% |
Q4 2018 | $6,528,000 | -9.9% | 63,309 | -5.0% | 4.27% | +14.3% |
Q3 2018 | $7,242,000 | +8.7% | 66,652 | -1.3% | 3.74% | +4.2% |
Q2 2018 | $6,661,000 | -0.1% | 67,497 | -0.9% | 3.58% | -1.7% |
Q1 2018 | $6,667,000 | +9.3% | 68,097 | +3.7% | 3.64% | +9.4% |
Q4 2017 | $6,098,000 | +6.3% | 65,697 | -1.7% | 3.33% | -1.4% |
Q3 2017 | $5,735,000 | +1.8% | 66,859 | +0.1% | 3.38% | -4.3% |
Q2 2017 | $5,634,000 | +1.3% | 66,765 | +2.7% | 3.53% | +1.6% |
Q1 2017 | $5,561,000 | +10.0% | 65,015 | +0.1% | 3.47% | +9.4% |
Q4 2016 | $5,055,000 | +0.8% | 64,940 | +1.5% | 3.17% | -1.2% |
Q3 2016 | $5,015,000 | +29.0% | 63,975 | +66.2% | 3.21% | +27.3% |
Q2 2016 | $3,888,000 | +9.2% | 38,500 | +2.5% | 2.52% | +6.1% |
Q1 2016 | $3,562,000 | +0.4% | 37,550 | -1.7% | 2.38% | +4.5% |
Q4 2015 | $3,548,000 | +12.2% | 38,200 | +3.0% | 2.28% | +3.2% |
Q3 2015 | $3,161,000 | – | 37,100 | – | 2.21% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |